129 related articles for article (PubMed ID: 30900620)
1. The effect of metabolic syndrome on prostate cancer final pathology.
Caliskan S; Kaba S; Özsoy E; Keleş MO; Koca O; Akyüz M; Karaman MI
J Cancer Res Ther; 2019 Mar; 15(Supplement):S47-S50. PubMed ID: 30900620
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
3. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
5. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study.
Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
[TBL] [Abstract][Full Text] [Related]
10. Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E; Carrasco-Valiente J; Campos-Hernández JP; Blanca-Pedregosa AM; Jiménez-Vacas JM; Ruiz-García J; Valero-Rosa J; Luque RM; Requena-Tapia MJ
J Cell Mol Med; 2019 Feb; 23(2):934-942. PubMed ID: 30450757
[TBL] [Abstract][Full Text] [Related]
11. The association of metabolic syndrome and its components with serum prostate-specific antigen levels.
Gao X; Bao T; Yang H; Lei Y; Jiang X; Huang Y; Huang W; Tang H
Eur J Cancer Prev; 2020 Jan; 29(1):36-41. PubMed ID: 30913093
[TBL] [Abstract][Full Text] [Related]
12. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
[TBL] [Abstract][Full Text] [Related]
13. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
14. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
[TBL] [Abstract][Full Text] [Related]
15. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.
Heidegger I; Klocker H; Pichler R; Pircher A; Prokop W; Steiner E; Ladurner C; Comploj E; Lunacek A; Djordjevic D; Pycha A; Plas E; Horninger W; Bektic J
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):271-275. PubMed ID: 28322234
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens.
Eminaga O; Hinkelammert R; Abbas M; Wötzel F; Eltze E; Bettendorf O; Boegemann M; Semjonow A
Urology; 2015 Oct; 86(4):798-804. PubMed ID: 26255036
[TBL] [Abstract][Full Text] [Related]
17. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
19. Impact of Prostate Specific Antigen Level on Oncological Outcomes after Open Radical Prostatectomy.
Sungur M; Caliskan S
J Coll Physicians Surg Pak; 2019 Apr; 29(4):361-364. PubMed ID: 30925962
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and prostate cancer in Afro-Caribbean men.
Lefebvre F; Blanchet-Deverly A; Michineau L; Blanchet P; Multigner L; Brureau L
Prostate; 2022 Feb; 82(3):359-365. PubMed ID: 34905623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
